Therapeutic effects of viral vector-mediated antiangiogenic gene transfer in malignant ascites

Human Gene Therapy

Volumn 12, Issue 14, 2001, Pages 1713-1729

  Hampl, M ^a   Tanaka, T ^a   Albert, P S ^a   Lee, J ^a   Ferrari, N ^a   Fine, H A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ENDOSTATIN; HYBRID PROTEIN; THROMBOCYTE FACTOR 4; VASCULOTROPIN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASCITES TUMOR; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CONTROLLED STUDY; DENSITY; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; GENE TARGETING; GENE TRANSFER; HUMAN; HUMAN CELL; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; TUMOR CELL; TUMOR GROWTH; TUMOR MODEL; TUMOR VASCULARIZATION;

ADENOVIRIDAE; ANGIOSTATINS; ANIMALS; APOPTOSIS; ASCITES; BLOTTING, NORTHERN; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL DIVISION; CELL MOVEMENT; CELLS, CULTURED; COLLAGEN; COLORING AGENTS; DOWN-REGULATION; ENDOSTATINS; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOKINES; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PLASMIDS; PLASMINOGEN; PLATELET FACTOR 4; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TETRAZOLIUM SALTS; THIAZOLES; TUMOR CELLS, CULTURED; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0034802845     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303401750476221     Document Type: Article

References (60)

1. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
2. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms
3. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: Novel concepts of angiostatic therapy from intravital videomicroscopy
4. Expression of angiostatin cDNA in a murine fibrosarcoma suppresses primary tumor growth and produces long-term dormancy of metastases
5. Endostatin binds to blood vessels in situ independent of heparan sulfate and does not compete for fibroblast growth factor-2 binding
6. Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice
7. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor
8. Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD
9. Vascular endothelial growth factor. Regulation by cell differentiation and activated second messenger pathways
10. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis
11. Endostatin induces endothelial cell apoptosis
12. Cloning, expression, and in vitro activity of human endostatin
13. Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas
14. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
15. Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma
16. Antiangio-genic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice
17. Molecular and biological properties of the vascular endothelial growth factor family of proteins
18. What is the evidence that tumors are angiogenesis dependent?
19. Antiangiogenic gene therapy
20. Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms
21. Therapeutic potential of the anti-angiogenesis drug TNP-470
22. Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest
23. Combined effects of radio-therapy and angiostatin gene therapy in glioma tumor model
24. A simplified system for generating recombinant adenoviruses
25. Antiangiogenesis treatment for gliomas: Transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo
26. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy
27. Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action
28. Vascular targeting of solid and ascites tumours with antibodies to vascular endothelial growth factor
29. Vascular permeability factor, an endothelial cell mitogen related to PDGF
30. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
31. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase
32. Angiostatin suppresses malignant glioma growth in vivo
33. Gene therapy strategies for tumor antiangiogenesis
34. Vascular endothelial growth factor is a secreted angiogenic mitogen
35. Multiple forms of angiostatin induce apoptosis in endothelial cells
36. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors
37. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides
38. Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity
39. Simplified production of a recombinant human angiostatin derivative that suppresses intracerebral glial tumor growth
40. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
41. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumor types in vivo
42. Angiostatin binds ATP synthase on the surface of human endothelial cells
43. Pathogenesis of ascites tumor growth: Vascular permeability factor, vascular hyperpermeability, and ascites fluid accumulation
44. Adeno-associated virus-mediated delivery of antiangiogenic factors as an antitumor strategy
45. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
46. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
47. Malignant ascites: A 2-year review from a teaching hospital
48. Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach
49. Interaction of endostatin with integrins implicated in angiogenesis
50. Malignant ascites of unknown origin
51. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence
52. Transplantability and antigenicity of two sublines of the TA3 tumor
53. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases
54. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid
55. Current status of antiangiogenic factors
56. Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth
57. Viral vector-targeted antiangiogenic gene therapy utilizing an angio-statin complementary DNA
58. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding
59. Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth